Transplantation and Cellular Therapy Journal

This study identified advanced age, high comorbidities, UCB, & PTCy haploidentical HCT as factors significantly benefiting survival with LTV. The heterogeneity of LTV survival benefits showed the importance of personalized clinical decisions. More: ow.ly/LVe650WsP3E

Caregivers have acute & persistent psychosocial distress throughout the pediatric HSCT process. In this issue, the caregiver experience is analyzed. A key outcome: Caregivers show resilience through optimism, strong family bonds & professional support tinyurl.com/bdeed4pw

Allo-HSCT continues to be key in treating SAA. While haplo-HSCT has created more treatment possibilities, it remains unclear which graft source is better. This study assesses the outcomes using G-CSF-primed peripheral blood (G-PB) as the graft source: ow.ly/bKc550WsOgJ

This retrospective study investigates the clinical significance of a ≥10% decrement in FEV1 measured by spirometry for predicting all-cause mortality in HSCT recipients over a period of 5 years. To read more about the findings, go here: ow.ly/RyNh50WsOcY

A @CIBMTR study examines CRS & ICANS in LBCL patients treated with CAR T therapies. Highlights: ICANS rates remain stable; CRS & ICANS are strongly correlated; Severe forms of these toxicities are associated with reduced overall survival. Read here: tinyurl.com/4tnurfas

The long-term results from two studies confirm the viability of belumosudil for treating cGVHD after a cell transplant. Read more in the July issue: tinyurl.com/4upydry8

While generally safe for patients with preexisting renal impairment, CAR T-cell therapy can create nephrotoxicity for those without it. For this reason, blood tests & urine analysis are imperative post-CAR T-cell infusion. Read: tinyurl.com/2t27yvd8

July’s journal issue features trial results on the effect of probiotic L plantarum in pediatric cancer patients. Researchers conclude that use of LBP 299v is safe for children & adolescents undergoing alloHCT but doesn’t prevent GI aGvHD. For more: tinyurl.com/2dykm3rd

Umbilical cord transplants are an important stem cell source for patients. Collecting & storing units globally provides flexible transplant timing & larger reach of patients. Concerns over naïve immune cells as less effective are unproven. Read here: tinyurl.com/5449j2zm

While CAR T-cell therapy is effective for some B-cell lymphoma patients, potentially life-threatening situations exist. In July’s issue, researchers stress that common & unusual toxicities must be tracked via registries, like @CIBMTR. Read: tinyurl.com/yh3tfuwk

A retrospective study found that early immunosuppression levels with post-transplant cyclophosphamide did not correlate with acute #GVHD incidence. However, levels ≥10 ng/mL were linked to poorer outcomes, highlighting the need to refine target ranges. ow.ly/GzKT50Wfzz3

The July issue of 'Transplantation and Cellular Therapy' is now available online. Check out the latest research in transplantation, cellular therapy and more: astctjournal.org/current @ELShematology

The updated @ASTCT Practice Guidelines App makes it easier than ever to access clinical tools, GVHD scoring, built-in calculators and more—right at your fingertips. If you haven’t downloaded it yet, now’s the time: astct.org/Education/Prac…

This study reports outcomes of non-myeloablative (NMA) #alloHCT for myelofibrosis in Eastern Denmark. NMA regimens showed satisfactory survival, with low one-year non-relapse mortality but high relapse risk. Read more: ow.ly/lbw850Wkz58

Now that gene therapies for SCD & TDT are commercially available, institutions are sharing best practices to optimize care. This review outlines key assessments, patient journey insights & supportive care for autologous gene therapy. Read the review: ow.ly/aweJ50Wkz3V

July is Cord Blood Awareness Month! 🧬 Explore our special collection spotlighting the latest research, innovations and clinical advances in cord blood transplantation and cellular therapy. Read the collection: ow.ly/Ytun50Wkz3C #CordBloodAwarenessMonth

This article reflects on the growing number of cancer & transplant survivors & the moral obligation to help them thrive. Long-term follow-up, survivorship care & adherence to research are key to ensuring a life saved becomes a life well-lived. Read more: ow.ly/WqQt50WkyQH

In this study, the 1-year incidence of infectious enterocolitis after #HCT with post-transplant cyclophosphamide was 19%. Bone marrow grafts and chronic #GVHD increased risk, but infectious enterocolitis did not affect overall transplant outcomes. astctjournal.org/article/S2666-…

High melphalan exposure increases the risk of engraftment syndrome and Grades II–IV acute #GVHD in pediatric patients undergoing T-cell depleted haploidentical transplantation. Many patients may need adjustments to BSA-based melphalan dosing. Read more: astctjournal.org/article/S2666-…

This study found that allogeneic stem cell transplantation after pembrolizumab therapy l—including for classical Hodgkin lymphoma—showed favorable progression-free and overall survival with low relapse and transplant-related mortality. Read more: astctjournal.org/article/S2666-…